Search Results - "Montelongo, Monica Z."

Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial by Tripathy, Debu, Blum, Joanne L, Karuturi, Meghan S, McCune, Steven, Kurian, Sobha, Moezi, Mehdi, Anderson, Daniel, Gauthier, Eric, Zhang, Zhe, Montelongo, Monica Z, Wang, Yao, Rocque, Gabrielle B

“…Strict eligibility criteria for participation in randomized clinical trials (RCTs) often limit the generalizability of data when applied to a more…”
Get full text

Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS by Rocque, Gabrielle B., Blum, Joanne L., Ji, Yan, Pluard, Timothy, Migas, John, Lakhanpal, Shailendra, Jepsen, Erin, Gauthier, Eric, Wang, Yao, Montelongo, Monica Z., Cappelleri, Joseph C., Karuturi, Meghan S., Tripathy, Debu

“…To evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative…”
Get full text

Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study by Blum, Joanne L., DiCristo, Caroline, Gordon, David, Karuturi, Meghan S., Oubre, David, Jepsen, Erin, Cuevas, Juan, Lakhanpal, Shailendra, Montelongo, Monica Z., Zhang, Zhe, Cappelleri, Joseph C., Wang, Yao, Tripathy, Debu

“…Purpose Data on treatments for male breast cancer patients are limited owing to rarity and underrepresentation in clinical trials. The real-world POLARIS study…”
Get full text

Measures of functional status in older patients treated with palbociclib for advanced breast cancer by Karuturi, Meghan S., Cappelleri, Joseph C., Blum, Joanne L., Patel, Kamal, Telivala, Bijoy, McCune, Steven, Cuevas, Juan Daniel, Lakhanpal, Shailendra, Montelongo, Monica Z., Wang, Yao, Tripathy, Debu, Rocque, Gabrielle B.

“…Limited data are available on the effects of treatment for advanced breast cancer (ABC) in older patients because this population has limited enrollment in…”
Get full text

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study by Cortes, Jorge E., Goldberg, Stuart L., Paquette, Ronald, Williams, Loretta A., Hehlmann, Rüdiger, Michallet, Mauricette, Gambacorti-Passerini, Carlo, Tang, Derek, DeGutis, Irene S., McBride, Ali, Parsons, Lori, Montelongo, Monica Z., Mauro, Michael

Get full text

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY) by Mauro, Michael, Paquette, Ronald, Hehlmann, Rüdiger, Williams, Loretta A., Goldberg, Stuart L., Michallet, Mauricette, Gambacorti-Passerini, Carlo, Tang, Derek, DeGutis, Irene S., McBride, Ali, Parsons, Lori, Montelongo, Monica Z., Cortes, Jorge E.

Get full text

Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS by Karuturi, Meghan S., Rocque, Gabrielle B., Cappelleri, Joseph C., Blum, Joanne L., McCune, Steven L., Telivala, Bijoy, Kurian, Sobha, Anderson, Daniel M., Tsai, Michaela, Pluard, Timothy, Migas, John, Wang, Yao, Montelongo, Monica Z., Tripathy, Debu

“…Background: POLARIS is an ongoing, prospective, real-world, noninterventional, multicenter study in patients with HR+/HER2- ABC receiving palbociclib in the…”
Get full text

Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS by Tripathy, Debu, Blum, Joanne L., Sleckman, Bethany, Patel, Kamal, Nakhoul, Ibrahim, Gauthier, Eric, Montelongo, Monica Z., Zhang, Zhe, Wang, Yao, Rocque, Gabrielle B.

“…Background: The cyclin-dependent kinase 4/6 inhibitor palbociclib (PAL) is approved for the treatment of HR+/HER2– advanced breast cancer (ABC) in combination…”
Get full text

Abstract P3-01-05: Laboratory monitoring in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer treated with palbociclib in a real-world setting: Results from POLARIS by Rocque, Gabrielle B., Blum, Joanne L., Specht, Jennifer M., Dul, Carrie, Corso, Steven, Cuevas, Daniel, Gauthier, Eric, Montelongo, Monica Z., Zhang, Zhe, Wang, Yao, Tripathy, Debu

“…Background: Palbociclib (PAL) is a cyclin-dependent kinase 4/6 inhibitor indicated for the treatment of HR+/HER2– advanced breast cancer (ABC) in combination…”
Get full text

Abstract P5-02-22: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib: Biomarker Results from POLARIS by Tripathy, Debu, Blum, Joanne L., Deng, Shibing, McCune, Steven L., Patel, Kamal, Wang, Yao, Lakhanpal, Shailendra, Karuturi, Meghan S., Zhang, Zhe, Deshpande, Chetan, Montelongo, Monica Z., Gauthier, Eric, Liu, Yuan, Rocque, Gabrielle B., Bardia, Aditya

“…Background: POLARIS is a prospective, real-world study of palbociclib in patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor…”
Get full text